Molecular and cellular properties of broad and protective immune responses to the Plasmodium falciparum variant surface antigen responsible for severe malaria

Malaria remains a global health problem, with nearly half the world’s population at risk of transmission. Of the many clinical outcomes of malaria, cerebral malaria is the major cause of death in children. Cerebral malaria is caused by the accumulation of infected erythrocytes in brain capillaries, resulting in reduced blood flow, lesions, brain swelling, and ultimately coma and death. The adhesion of infected erythrocytes to host receptors found on brain endothelium is facilitated by the variant surface antigen Plasmodium falciparum erythrocyte membrane protein 1 (PfEMP1). Specifically, cysteine-rich interdomain region alpha 1 (CIDRa1) domains in PfEMP1 mediate binding to host endothelial protein C receptor (EPCR). Children in malaria-endemic regions who overcome the initial clinical complications of the disease rapidly develop immunity against cerebral malaria, resulting from the acquisition of antibodies targeting CIDRa1. Given the high sequence variation among CIDRa1 variants and the quick waning of antibody responses against other P. falciparum proteins, it is unclear how this protection is achieved and maintained over time. Preliminary work has revealed that monoclonal antibodies from malaria- protected adults can recognize multiple CIDRa1 variants despite their sequence diversity and inhibit the binding of these CIDRa1 variants to EPCR. It was also observed that a substantial percentage of CIDRa1-targeting B cells possessed an atypical B cell phenotype. Based on our preliminary data, the hypothesis is that broadly reactive antibodies against CIDRa1 target diverse epitopes around the EPCR-binding site and are generated in conjunction with long-lasting B cell memory. The results from this study will enhance our understanding of the nature and durability of protective immunity and advance the design of a vaccine that elicits broad and long-lived protection against malaria pathogenesis.

Project details

Vaccines (Immune Correlates)

May 2022 — Apr 2024

$72,926

United States